Edyta Biskup

Feb 4, 2024 | onlinelibrary.wiley.com | Uffe H. Olesen |Kristian Pedersen |Katrine Togsverd-Bo |Edyta Biskup

INTRODUCTION Hedgehog inhibitors emerged in 2012 as the first class of drugs approved specifically for the treatment of locally advanced and metastatic basal cell carcinoma (BCC) as vismodegib received approval from the US Food and Drug Administration.1, 2 Hedgehog inhibitors target aberrant activation of hedgehog pathway signaling that is observed in practically all BCCs and appears crucial for tumor development.3 All currently approved hedgehog inhibitors, including vismodegib and...